HAE or SYK: Which Is the Better Value Stock Right Now?

Core Insights - The article compares Haemonetics (HAE) and Stryker (SYK) to determine which stock presents a better value opportunity for investors [1] Valuation Metrics - Haemonetics has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to Stryker, which has a Zacks Rank of 3 (Hold) [3] - HAE's forward P/E ratio is 17.88, significantly lower than SYK's forward P/E of 30.75, suggesting HAE may be undervalued [5] - The PEG ratio for HAE is 1.27, while SYK's PEG ratio is 2.80, indicating HAE's expected earnings growth is more favorable relative to its price [5] - HAE's P/B ratio stands at 4.78, compared to SYK's P/B of 7.02, further supporting HAE's valuation as more attractive [6] Value Grades - HAE has a Value grade of B, while SYK has a Value grade of C, indicating that HAE is perceived as a better value investment at this time [7]